Optimizing antigen preparation for oxalyl-CoA decarboxylase enzyme diagnostic kit and ELISA system cutoff determination.


Journal

Urolithiasis
ISSN: 2194-7236
Titre abrégé: Urolithiasis
Pays: Germany
ID NLM: 101602699

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 11 06 2024
accepted: 30 09 2024
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 9 10 2024
Statut: epublish

Résumé

The prevalence of kidney stone disease is increasing globally, with calcium oxalate stones being the most common type. Oxalyl-CoA decarboxylase (OXC), an enzyme produced by the gut bacterium Oxalobacter formigenes, plays a crucial role in oxalate metabolism. Deficiencies in OXC activity can lead to the accumulation of oxalate, contributing to kidney stone formation. This study aimed to develop a reliable diagnostic assay for OXC by optimizing antigen production and establishing a cutoff value for an enzyme-linked immunosorbent assay (ELISA). We cloned, expressed, and purified recombinant OXC protein in Escherichia coli BL21(DE3), and generated specific polyclonal antibodies in rabbits. The ELISA system was optimized and validated using serum samples from 40 healthy individuals and 6 patients with oxalate-related disorders. The cutoff value was determined using the formula (M + 2SD), where (M) is the mean and (SD) is the standard deviation of the healthy sample results. The calculated cutoff value of 0.656750 effectively distinguished between healthy and affected individuals, with a sensitivity of 97.5% and a specificity of 83.3%. These findings provide a valuable tool for the early detection and management of oxalate-related disorders, with significant implications for clinical practice.

Identifiants

pubmed: 39382754
doi: 10.1007/s00240-024-01635-7
pii: 10.1007/s00240-024-01635-7
doi:

Substances chimiques

oxalyl CoA decarboxylase EC 4.1.1.8
Carboxy-Lyases EC 4.1.1.-
Recombinant Proteins 0
Reagent Kits, Diagnostic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

141

Subventions

Organisme : The present study was carried out in the Cellular & Molecular Biology Research Center of Shahid Beheshti University of Medical Sciences, Tehran, Iran. and supported by Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
ID : 898

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Stamatelou K, Goldfarb DS (2023) Epidemiology of kidney stones. Healthc (Basel) 11(3)
Shin S, Srivastava A, Alli NA, Bandyopadhyay BC (2018) Confounding risk factors and preventative measures driving nephrolithiasis global makeup. World J Nephrol 7(7):129–142
doi: 10.5527/wjn.v7.i7.129 pubmed: 30510912 pmcid: 6259033
Elshal AM, Shamshoun H, Awadalla A, Elbaz R, Ahmed AE, El-Khawaga OY, Shokeir AA (2023) Hormonal and molecular characterization of calcium oxalate stone formers predicting occurrence and recurrence. Urolithiasis 51(1):76
doi: 10.1007/s00240-023-01440-8 pubmed: 37093310 pmcid: 10125924
Lung HY, Cornelius JG, Peck AB (1991) Cloning and expression of the oxalyl-CoA decarboxylase gene from the bacterium, Oxalobacter formigenes: prospects for gene therapy to control Ca-oxalate kidney stone formation. Am J Kidney Dis 17(4):381–385
doi: 10.1016/S0272-6386(12)80627-5 pubmed: 2008903
Youssef HIA (2024) Detection of oxalyl-CoA decarboxylase (oxc) and formyl-CoA transferase (frc) genes in novel probiotic isolates capable of oxalate degradation in vitro. Folia Microbiol (Praha) 69(2):423–432
Troxel SA, Sidhu H, Kaul P, Low RK (2003) Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol 17(3):173–176
doi: 10.1089/089277903321618743 pubmed: 12803990
Wigner P, Bijak M, Saluk-Bijak J (2022) Probiotics in the prevention of the calcium oxalate urolithiasis. Cells 11(2):284
doi: 10.3390/cells11020284 pubmed: 35053400 pmcid: 8773937
Abarghooi-Kahaki F, Basiri A, Bandehpour M, Kazemi B (2019) Designing a diagnostic kit for Oxalyl CoA decarboxylase enzyme by ELISA method. Immunol Lett 205:78–83
doi: 10.1016/j.imlet.2018.11.008 pubmed: 30447308
Kahaki FA, Dehnavi SM (2022) Expression optimizing of recombinant Oxalyl-CoA decarboxylase in Escherichia coli. Adv Biomedical Res 11(1):110
doi: 10.4103/abr.abr_244_21
Sorensen H, Mortensen K (2005) Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 115:113–128
doi: 10.1016/j.jbiotec.2004.08.004 pubmed: 15607230
Kalantari E, Bandehpour M, Pazoki R, Taghipoor-Lailabadi N, Khazan H, Mosaffa N et al (2010) Application of recombinant Echinococcus granulosus antigen B to ELISA kits for diagnosing hydatidosis. Parasitol Res 106(4):847–851
doi: 10.1007/s00436-010-1726-0 pubmed: 20143095
Bandehpour M, Seyed N, Shadnoosh M, Pakzad P, Kazemi B (2006) Using recombinant Chlamydia major outer membrane protein (MOMP) in ELISA diagnostic kit. Iran J Biotech 4:239–244
Mitchell T, Kumar P, Reddy T, Wood KD, Knight J, Assimos DG, Holmes RP (2019) Dietary oxalate and kidney stone formation. Am J Physiol Ren Physiol 316(3):F409–f13
doi: 10.1152/ajprenal.00373.2018
Jiang T, Chen W, Cao L, He Y, Zhou H, Mao H (2020) Abundance, functional, and evolutionary analysis of Oxalyl-Coenzyme a decarboxylase in human microbiota. Front Microbiol 11:672
doi: 10.3389/fmicb.2020.00672 pubmed: 32390974 pmcid: 7190790
Zhao C, Yang H, Zhu X, Li Y, Wang N, Han S et al (2017) Oxalate-degrading enzyme recombined lactic acid bacteria strains reduce hyperoxaluria. Urology 113

Auteurs

Davood Khavari Ardestani (DK)

Urology and Nephrology Research Center (UNRC), Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.

Abbas Basiri (A)

Urology and Nephrology Research Center (UNRC), Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.

Mojgan Bandehpour (M)

Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 1968917313, Iran.

Afshin Abdi-Ghavidel (A)

Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 1968917313, Iran.

Bahram Kazemi (B)

Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. khavarid@gmail.com.
Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 1968917313, Iran. khavarid@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH